Buprenorphine prescribing: Why physicians aren't and nurse prescribers can't

Journal of Addictions Nursing

Volumn 20, Issue 4, 2009, Pages 218-226

  Fornili, Katherine ^a   Burda, Charon ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

Author keywords

Advanced practice nurses (APNs); Buprenorphine access; Buprenorphine prescribing; Explanatory model for policy analysis; Geelhoed schouwstra framework; Nurse practitioners (NPs); Nurse prescribers; Opioid addiction; Policy analysis; Prescriptive authority

Indexed keywords

EID: 71449120706     PISSN: 10884602     EISSN: 15487148     Source Type: Journal    
DOI: 10.3109/10884600903290424     Document Type: Article

References (43)

1. Alford, D.P., LaBelle, C.T., Richardson, J.M., O'Connell, J.J., Hohl, C.A., Cheng, D.M. & Samet, J.H. (2007). Treating homeless opioid dependent patients with buprenorphine in an office-based setting. Journal of General Internal Medicine, 22(2), 171-176.
2. American Academy of Nurse Practitioners. (2007a). Nurse practitioner cost-effectiveness. Washington, DC: Author. Retrieved August 24, 2009, from http://www.aanp.org/NR/rdonlyres/197C9C42-4BC1-42A5-911E-85FA759B0308/0/ NPCostEff112907.pdf.
3. American Academy of Nurse Practitioners. (2007b). Quality of nurse practitioner practice. Washington, DC: Author. Retrieved August 24, 2009, from http://www.aanp.org/NR/rdonlyres/34E7FF57-E071-4014-B554-FF02B82FF2F2/0/ QualityofNPPrac112907.pdf.
4. American Academy of Nurse Practitioners. (2007c). Use of terms such as midlevel provider and physician extender. Washington, DC: Author. Retrieved August 24, 2009, from http://www.aanp.org/NR/rdonlyres/5AC2D9E3-74FA-4BF2-BF2F- 1E424A62E516/0/MLP.pdf.
5. Azimi-Bolourian, S. & Fornili, K. (2009). Buprenorphine: A guide for nurses. Technical Assistance Publication (TAP) Series 30. DHHS Publication No. (SMA) 09-4376. Rockville, MD: Substance Abuse and Mental Health Services Administration.
6. Berry, P.H. & Dahl, J.L. (September/October 2007). Advanced practice nurse controlled substances prescriptive authority: A review of the regulations and implications for effective management at end-of-life. Journal of Hospice and Palliative Nursing, 9(5), 238-245.
7. Brewington, K. (August 9, 2009). Picking up the slack in primary medicine. The Baltimore Sun, p. 114.
8. Center for Healthy Maryland, Inc. MedChi, The Maryland State Medical Society. (2007). Improving patient access to buprenorphine treatment through physician offices in Maryland: A summary of findings, recommendations, and action steps. Accessed August 25, 2009 from http://www.healthymaryland.org/pdf/ Improving%20Patient%20Access%20for%20Bup%20Treatment.pdf.
9. Center for Substance Abuse Treatment (CSAT). (2004). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville,MD:Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment-Substance Abuse and Mental Health Services Administration (CSAT-SAMHSA) and the National Institute on Drug Abuse-National Institutes of Health (NIDA-NIH). Buprenorphine in the treatment of opioid addiction: Expanding access-enhancing quality. Summary of work group reports. Accessed August 23, 2009 from http://buprenorphine.samhsa.gov/presentations/ 2008WorkGroupReports2%2029%2008-2.pdf.
10. Chappel, J.N. (1992). Attitudes toward the treatment of substance abusers. In: Lowenson, J., Ruiz, P., & Millman, R., (Eds). Comprehensive textbook of substance abuse. Baltimore, MD: Williams and Wilkins, p. 983-996.
11. Courtenay, M. & Berry, D. (2007). Comparing nurses' and doctors' views of nurse prescribing: a questionnaire survey. Nurse Prescribing, 5(5), 205-210.
12. Doescher, M.P. & Saver, B.G. (2000). Physicians' advice to quit smoking: The glass remains half empty. Journal of Family Practice, 49(6), 543-547.
13. Federation of State Medical Boards of the United States, Inc. (April 2002). Model policy guidelines for opioid addiction treatment in the medical office. Retrieved August 23, 2009 from http://buprenorphine.samhsa.gov/model. html.
14. Fornili, K. (2007). Another quality chasm: The failure of nursing to clearly communicate its role within the addiction treatment workforce. Journal of Addiction Nursing, 18(1), 57-59.
15. Fornili, K. (2008). Integrated treatment for women with co-occurring disorders and an explanatory model for policy analysis and evaluation. Journal of Addiction Nursing, 19(3), 109-118.
16. Fornili, K. & Burda-Cohee, C. (2006). Buprenorphine products for the pharmacologic management of opioid addiction: Why shouldn't advanced practice nurses prescribe? Journal of Addiction Nursing, 17(2), 139-145.
17. Geller, G., Levine, D.M., Mamon, R.D., Moore, R.D., Bone, L.R. & Stokes, E.J. (1989). Knowledge, attitudes and reported practices of medical students and housestaff regarding the diagnoses and treatment of alcoholism. JAMA, 261, 3115-3120.
18. Gordon, S. (2005). Nursing against the odds. Ithaca, NY: Cornell University Press.
19. Group, T.M. & Roberts, J.I. (2001). Nursing, physician control, and the medical monopoly: Historical perspectives on gendered inequality in roles, rights, and range of practice. Bloomington, IN: Indiana University Press.
20. Hser, Y.I., Maglione, M., Polinsky, M.L., Anglin, M.D. (1998). Predicting drug treatment entry among treatment-seeking individuals. Journal of Substance Abuse Treatment, 15, 213-220, in Thomas, Reif, Haq et al., 2008.
21. Join Together. (2003). National poll of physicians on barriers to widespread buprenorphine use. Accessed August 23, 2009 from http://www. jointogether.org/aboutus/ourpublications/pdf/bupereport.pdf.
22. Kritek, P.B. (2002). Negotiating at an uneven table: Developing courage in resolving our conflicts. 2nd Ed. San Francisco, CA: Jossey-Bass.
23. Mark, T.L., Kassed, C.A., Vandivort-Warren, R., Levit, K.R. & Kranzler, H.R. (2008). Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug and Alcohol Dependence, 99, 345-349.
24. Medline Plus Medical Encyclopedia. (July 22, 2008). Nurse Practitioner. Accessed August 23, 2009 from http://www.nlm.nih.gov/medlineplus/ency/article/ 001934.htm#Definition.
25. McLellan, A.T.,Woody, G.E., Metzger, D., McKay, J.,Durell, J.,Alterman, A.I., & O'Brien, C.P. (1996). Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. Milbank Quarterly, 74, 51-85.
26. O'Brien, C.P.,&McLellan, A.T. (1996).Myths about the treatment of addiction. Lancet, 347, 237-240.
27. Olsen, Y., Bass, E., McCaul, M.E. & Steinwachs, D. (2004). Treating opioid addiction in office-based settings: Findings from a physician survey. Johns Hopkins University School of Medicine and Johns Hopkins Bloomberg School of Public Health. Accessed August 25, 2009 from http://www.healthymaryland.org/ pdf/2004%20Physician%20Survey.pdf.
28. Pearson, L. (February 2008). The Pearson Report: A national overview of nurse practitioner legislation and healthcare issues-c . The American Journal for Nurse Practitioners, 12(2), 9-80.
29. Pearson, L. (February 2009). The Pearson Report: A national overview of nurse practitioner legislation and healthcare issues-c . The American Journal for Nurse Practitioners, 13(2), 8-71.
30. Pond, M.H. (2009). Buprenorphine treatment: A nurse's story. SAMHSA News, 17(3), 1. Accessed August 1, 2009 from http://www.samhsa.gov/ samhsaNewsletter/Volume17Number3/NurseManagersStory.aspx.
31. Roose, R.J., Kunins, H.V., Sohler, N.L., Elam, R.T., & Cunningham, C.O. (2008). Nurse practitioner and physician assistant interest in prescribing buprenorphine. Journal of Substance Abuse Treatment, 34(4), 456-459. Accessed August 25, 2009, http://www.rwjf.org/pr/product.jsp?id=30581
32. Roots, R.I. (2004). When laws backfire: Unintended consequences of public policy. American Behavioral Scientist, 47(11), 1376-1394.
33. Samet, J.H., Friedmann, P., & Saitz, R. (January 8, 2001). Benefits of linking primary medical care and substance abuse services. Archives of Internal Medicine, 161, 85-91.
34. Schackman, B.R., Merrill, J.O., McCarty, D., Levi, J., & Lubinski, C. 2006. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clinical Infectious Diseases, 43(Suppl 4), S247-S253.
35. Schouwstra, M. & Ellman, M. (2006). A new explanatory model for policy analysis and evaluation. Tinbergen Institute Discussion Paper. Amsterdam: Universiteit van Amsterdam and Tinbergen Institute. TI 2006-063/2. Accessed August 23, 2009 from http://papers.ssrn.com/sol3/papers.cfm?abstractid=917327.
36. Substance Abuse and Mental Health Services Administration-Center for Substance Abuse Treatment. (January 2001). E. Strain (ed). The use of buprenorphine in the pharmacologic management of opioid dependence: A curriculum for physicians. Accessed August 23, 2009 from http://buprenorphine.samhsa.gov/ BuprenorphineCurriculum.pdf.
37. Substance Abuse and Mental Health Services Administration (SAMHSA). (2006). National survey on drug use and health, 2005. Rockville, MD: SAMHSA Office of Applied Studies. Accessed from www.icpsr.umich.edu/cocoon/ICPSR/STUDY/ 04596.xml, by Thomas, Reif, Haq, et al., 2008.
38. Substance Abuse and Mental Health Services Administration (SAMHSA). (March 30, 2006). The SAMHSA evaluation of the impact of the DATA Waiver Program: Summary report. Task Order 277-00-6111. AccessedAugust 23, 2009 from http://buprenorphine.samhsa.gov/FOR FINAL summaryreport colorized.pdf.
39. Thomas, C.P., Reif, S., Haq, S., Wallack, S.S., Hoyt, A., & Ritter, G.A. (2008). Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatric Services, 59(8), 909-916.
40. Thomas, C.P., Wallack, S.S., Lee, S., McCarty, D. & Swift, R. (2003). Research to practice: adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment, 24(1), 1-11.
41. Turner, B.J., Laine, C., Lin, Y., & Lynch, K. (August 22, 2005). Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Archives of Internal Medicine, 165, 1769-1776.
42. U.S. Department of Health and Human Services. (2000). Drug Addiction Treatment Act of 2000. Public Law No. 106-310. Title XXXV-Waiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment. Retrieved August 23, 2009 from http://buprenorphine.samhsa.gov/data.html.
43. U.S. Department of Health and Human Services. (n.d.). Substance Abuse and Mental Health Services Administration Strategic Plan for Fiscal Years 2006-2011. Rockville, MD: Substance Abuse and Mental Health Services Administration.